Search

Your search keyword '"Basun H"' showing total 287 results
Start Over Author "Basun H"
287 results on '"Basun H"'

9. Regulation of Aβ levels in human plasma: 218

Author

Giedraitis, V., Irizarry, M. C., Sundelöf, J., Gunnarsson, M. Degermann, Kilander, L., Glaser, A., Ingelsson, M., Hyman, B. T., Basun, H., and Lannfelt, L.

Published
2007

12. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment

Author

WINBLAD, B., PALMER, K., KIVIPELTO, M., JELIC, V., FRATIGLIONI, L., WAHLUND, L.-O., NORDBERG, A., BÄCKMAN, L., ALBERT, M., ALMKVIST, O., ARAI, H., BASUN, H., BLENNOW, K., DE LEON, M., DECARLI, C., ERKINJUNTTI, T., GIACOBINI, E., GRAFF, C., HARDY, J., JACK, C., JORM, A., RITCHIE, K., VAN DUIJN, C., VISSER, P., and PETERSEN, R. C.

Published
2004

19. SUN-LB035: Does APOE4 Carriership Influence Potential Omega-3 Fatty Acid Treatment Effects on Cognition or Psychiatric Status in Patients With Mild to Moderate Alzheimer’S Disease: The Omegad Study

Author

Freund-Levi, Y., primary, Falahati, F., additional, Hjorth, E., additional, Cederholm, T., additional, Eriksdotter, M., additional, Vedin, I., additional, Faxen-Irving, G., additional, Wahlund, L.-O., additional, Schultzberg, M., additional, Basun, H., additional, and Palmblad, J., additional

Published
2015
Full Text
View/download PDF

20. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the OmegAD study

Author

Freund Levi, Y., primary, Vedin, I., additional, Cederholm, T., additional, Basun, H., additional, Faxén Irving, G., additional, Eriksdotter, M., additional, Hjorth, E., additional, Schultzberg, M., additional, Vessby, B., additional, Wahlund, L.-O., additional, Salem, N., additional, and Palmblad, J., additional

Published
2014
Full Text
View/download PDF

23. Genetic counseling in a Swedish Alzheimer family with amyloid precursor protein mutation

Author

Lannfelt, L, Axelman, K, Lilius, L, and Basun, H

Subjects
Adult, Male, Risk, Sweden, Suicide Prevention, Amyloid, Letter, Prions, DNA Mutational Analysis, Emotions, Genetic Counseling, Middle Aged, Prion Proteins, Pedigree, Alzheimer Disease, Mutation, Humans, Female, Genetic Testing, Age of Onset, Protein Precursors, Aged
Published
1995

28. Serum cystatin C and the risk of Alzheimer disease in elderly men

Author

Sundelof, J., primary, Arnlov, J., additional, Ingelsson, E., additional, Sundstrom, J., additional, Basu, S., additional, Zethelius, B., additional, Larsson, A., additional, Irizarry, M. C., additional, Giedraitis, V., additional, Ronnemaa, E., additional, Degerman-Gunnarsson, M., additional, Hyman, B. T., additional, Basun, H., additional, Kilander, L., additional, and Lannfelt, L., additional

Published
2008
Full Text
View/download PDF

33. Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer's disease: the Omeg AD study.

Author

Freund Levi, Y., Vedin, I., Cederholm, T., Basun, H., Faxén Irving, G., Eriksdotter, M., Hjorth, E., Schultzberg, M., Vessby, B., Wahlund, L.‐O., Salem, N., and Palmblad, J.

Subjects
OMEGA-3 fatty acids, EICOSAPENTAENOIC acid, ALZHEIMER'S patients, CEREBROSPINAL fluid, PLACEBOS
Abstract

Objective Little is known about the transfer of essential fatty acids ( FAs) across the human blood-brain barrier ( BBB) in adulthood. In this study, we investigated whether oral supplementation with omega-3 ( n-3) FAs would change the FA profile of the cerebrospinal fluid ( CSF). Methods A total of 33 patients (18 receiving the n-3 FA supplement and 15 receiving placebo) were included in the study. These patients were participants in the double-blind, placebo-controlled randomized Omeg AD study in which 204 patients with mild Alzheimer's disease ( AD) received 2.3 g n-3 FA [high in docosahexaenoic acid ( DHA)] or placebo daily for 6 months. CSF FA levels were related to changes in plasma FA and to CSF biomarkers of AD and inflammation. Results At 6 months, the n-3 FA supplement group displayed significant increases in CSF (and plasma) eicosapentaenoic acid ( EPA), DHA and total n-3 FA levels ( P < 0.01), whereas no changes were observed in the placebo group. Changes in CSF and plasma levels of EPA and n-3 docosapentaenoic acid were strongly correlated, in contrast to those of DHA. Changes in DHA levels in CSF were inversely correlated with CSF levels of total and phosphorylated tau, and directly correlated with soluble interleukin-1 receptor type II. Thus, the more DHA increased in CSF, the greater the change in CSF AD/inflammatory biomarkers. Conclusions Oral supplementation with n-3 FAs conferred changes in the n-3 FA profile in CSF, suggesting transfer of these FAs across the BBB in adults. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

34. High Tau Levels in Cerebrospinal Fluid Predict Rapid Decline and Increased Dementia Mortality in Alzheimer's Disease.

Author

Degerman Gunnarsson, M., Lannfelt, L., Ingelsson, M., Basun, H., and Kilander, L.

Subjects
ALZHEIMER'S disease diagnosis, CEREBROSPINAL fluid examination, BIOMARKERS, CONFIDENCE intervals, STATISTICAL correlation, DEMENTIA, EPIDEMIOLOGY, LONGITUDINAL method, NEUROPSYCHOLOGICAL tests, PROTEINS, RESEARCH funding, LUMBAR puncture, STATISTICS, LOGISTIC regression analysis, DATA analysis, PREDICTIVE validity, PROPORTIONAL hazards models, RETROSPECTIVE studies, SEVERITY of illness index, DISEASE progression, DESCRIPTIVE statistics
Abstract

Objective: Cerebrospinal fluid (CSF) amyloid β42 (Aβ42), total tau (t-tau) and phosphorylated tau (p-tau) are useful as predictors of conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia. However, results are contradictory as to whether these biomarkers reflect the future rate of clinical decline. Methods: This is a retrospective study on 196 patients with AD [mild/moderate AD (n = 72) or AD-MCI (n = 124) at baseline] with a follow-up period of 2-9 years' duration (median 6 years). Lumbar punctures were performed at baseline as a part of the diagnostic procedure. Results: We found an increased risk of rapid cognitive decline defined as a drop in the Mini-Mental State Examination score of ≥4 points/year in patients with CSF t-tau concentrations above the median (OR 3.31, 95% CI 1.53-7.16) and CSF p-tau above the median (OR 2.53, 95% CI 1.21-5.26). Patients with CSF t-tau in the highest quartile had a higher risk of dying in severe dementia (HR 4.67, 95% CI 1.16-18.82). Conclusions: In this large AD cohort, we found an association between high levels of CSF t-tau and p-tau and a more aggressive course of the disease, measured as a rapid cognitive decline and a higher risk of dying in severe dementia. © 2013 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

50. Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia.

Author

Olsson B, Hertze J, Lautner R, Zetterberg H, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Blennow K, Hansson O, Olsson, Bob, Hertze, Joakim, Lautner, Ronald, Zetterberg, Henrik, Nägga, Katarina, Höglund, Kina, and Basun, Hans

Abstract

Microglia manage immunosurveillance and mediate inflammation, both suggested to be important in Alzheimer's disease (AD). The aim of this study was to investigate if microglial markers could differentiate, firstly between AD and controls, and secondly between stable mild cognitive impairment (MCI) and those progressing to AD and vascular dementia (VaD). Furthermore, we investigated if these markers were sufficiently stable to be used in clinical trials. We quantified YKL-40 and sCD14 in cerebrospinal fluid (CSF) from 96 AD patients, 65 healthy controls, and 170 patients with MCI from baseline and over 5.7 years. For the stability analysis, two CSF samples were collected from 52 AD patients with a six-month interval in between. YKL-40, but not sCD14, was significantly elevated in AD compared with healthy controls (p = 0.003). Furthermore, YKL-40 and sCD14 were increased in MCI patients who converted to VaD (p = 0.029 and p = 0.008), but not to AD according to NINCDS-ADRDA. However, when stratified according to CSF levels of tau and Aβ42, YKL-40 was elevated in those with an AD-indicative profile compared with stable MCI with a normal profile (p = 0.037). In addition, YKL-40 and sCD14 were very stable in AD patients with good correlation between time-points (r = 0.94, p = 3.4 × 10-25; r = 0.77, p = 2.0 × 10-11) and the cortical damage marker T-tau. Thus, microglial markers are stable and may be used as safety markers for monitoring CNS inflammation and microglia activation in clinical trials. Moreover, YKL-40 differentiates between AD and controls and between stable MCI to AD and those that convert to AD and VaD. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results